The 3Rs of Cell Therapy
The 3Rs for a good education are “reading, 'riting, and 'rithmetic.” The basis for good health care solutions for the emergent field of cell therapy in the future will also involve 3Rs: regulation, reimbursement, and realization of value. The business models in this new field of cell thera...
Gespeichert in:
| Veröffentlicht in: | Stem cells translational medicine 2017-01, Vol.6 (1), p.17-21 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 21 |
|---|---|
| container_issue | 1 |
| container_start_page | 17 |
| container_title | Stem cells translational medicine |
| container_volume | 6 |
| creator | Caplan, Arnold I. Mason, Chris Reeve, Brock |
| description | The 3Rs for a good education are “reading, 'riting, and 'rithmetic.” The basis for good health care solutions for the emergent field of cell therapy in the future will also involve 3Rs: regulation, reimbursement, and realization of value. The business models in this new field of cell therapy will involve these 3Rs. This article brings forth realities facing this new industry for its approaches to provide curative health care solutions. Stem Cells Translational Medicine 2017;6:17–21 |
| doi_str_mv | 10.5966/sctm.2016-0180 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5442742</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2289828384</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5303-2ee0db1f383e344f3ad4f0a741e8ce8d4b3cabee66f5a47e2af436b285b9cc4e3</originalsourceid><addsrcrecordid>eNqFkM1LwzAYh4Mobsxd9SYDL1468930IkjxCwaCznNI07euox8zWZX996ZsDvViLknIkx_v70HolOCpSKS88nZdTykmMsJE4QM0pETEkRQKH-7Pkg_Q2PslDksmMqH4GA2oIjEmMRuis_kCJuzZT9pikkJVTcLdmdXmBB0VpvIw3u0j9Hp3O08fotnT_WN6M4usYJhFFADnGSmYYsA4L5jJeYFNzAkoCyrnGbMmA5CyEIbHQE3BmcyoElliLQc2Qtfb3FWX1ZBbaNbOVHrlytq4jW5NqX-_NOVCv7UfWnBOY05DwOUuwLXvHfi1rktvQxPTQNt5TVTwEchEBvTiD7psO9eEeppSlSiqmOKBmm4p61rvHRT7YQjWvXbda9e9dt1rDx_Of1bY49-SAyC2wGdZweafOP2SzhmhmDL2BStbjPU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2289828384</pqid></control><display><type>article</type><title>The 3Rs of Cell Therapy</title><source>Wiley Online Library - AutoHoldings Journals</source><source>DOAJ Directory of Open Access Journals</source><source>Access via Oxford University Press (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Caplan, Arnold I. ; Mason, Chris ; Reeve, Brock</creator><creatorcontrib>Caplan, Arnold I. ; Mason, Chris ; Reeve, Brock</creatorcontrib><description>The 3Rs for a good education are “reading, 'riting, and 'rithmetic.” The basis for good health care solutions for the emergent field of cell therapy in the future will also involve 3Rs: regulation, reimbursement, and realization of value. The business models in this new field of cell therapy will involve these 3Rs. This article brings forth realities facing this new industry for its approaches to provide curative health care solutions. Stem Cells Translational Medicine 2017;6:17–21</description><identifier>ISSN: 2157-6564</identifier><identifier>EISSN: 2157-6580</identifier><identifier>DOI: 10.5966/sctm.2016-0180</identifier><identifier>PMID: 28170173</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Baby boomers ; Biotechnology industry ; Bone marrow ; Business models ; Disease ; FDA approval ; GDP ; Gross Domestic Product ; Health care ; Market positioning ; Medical device industry ; Medical equipment ; Medical technology ; Patients ; Product lines ; Regulation ; Regulatory approval ; Stem cells ; Success</subject><ispartof>Stem cells translational medicine, 2017-01, Vol.6 (1), p.17-21</ispartof><rights>2016 The Authors published by Wiley Periodicals, Inc. on behalf of AlphaMed Press</rights><rights>2016 The Authors Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.</rights><rights>2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2016 The Authors S C T M published by Wiley Periodicals, Inc. on behalf of AlphaMed Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5303-2ee0db1f383e344f3ad4f0a741e8ce8d4b3cabee66f5a47e2af436b285b9cc4e3</citedby><cites>FETCH-LOGICAL-c5303-2ee0db1f383e344f3ad4f0a741e8ce8d4b3cabee66f5a47e2af436b285b9cc4e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442742/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442742/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,1418,11567,27929,27930,45579,45580,46057,46481,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28170173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caplan, Arnold I.</creatorcontrib><creatorcontrib>Mason, Chris</creatorcontrib><creatorcontrib>Reeve, Brock</creatorcontrib><title>The 3Rs of Cell Therapy</title><title>Stem cells translational medicine</title><addtitle>Stem Cells Transl Med</addtitle><description>The 3Rs for a good education are “reading, 'riting, and 'rithmetic.” The basis for good health care solutions for the emergent field of cell therapy in the future will also involve 3Rs: regulation, reimbursement, and realization of value. The business models in this new field of cell therapy will involve these 3Rs. This article brings forth realities facing this new industry for its approaches to provide curative health care solutions. Stem Cells Translational Medicine 2017;6:17–21</description><subject>Baby boomers</subject><subject>Biotechnology industry</subject><subject>Bone marrow</subject><subject>Business models</subject><subject>Disease</subject><subject>FDA approval</subject><subject>GDP</subject><subject>Gross Domestic Product</subject><subject>Health care</subject><subject>Market positioning</subject><subject>Medical device industry</subject><subject>Medical equipment</subject><subject>Medical technology</subject><subject>Patients</subject><subject>Product lines</subject><subject>Regulation</subject><subject>Regulatory approval</subject><subject>Stem cells</subject><subject>Success</subject><issn>2157-6564</issn><issn>2157-6580</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkM1LwzAYh4Mobsxd9SYDL1468930IkjxCwaCznNI07euox8zWZX996ZsDvViLknIkx_v70HolOCpSKS88nZdTykmMsJE4QM0pETEkRQKH-7Pkg_Q2PslDksmMqH4GA2oIjEmMRuis_kCJuzZT9pikkJVTcLdmdXmBB0VpvIw3u0j9Hp3O08fotnT_WN6M4usYJhFFADnGSmYYsA4L5jJeYFNzAkoCyrnGbMmA5CyEIbHQE3BmcyoElliLQc2Qtfb3FWX1ZBbaNbOVHrlytq4jW5NqX-_NOVCv7UfWnBOY05DwOUuwLXvHfi1rktvQxPTQNt5TVTwEchEBvTiD7psO9eEeppSlSiqmOKBmm4p61rvHRT7YQjWvXbda9e9dt1rDx_Of1bY49-SAyC2wGdZweafOP2SzhmhmDL2BStbjPU</recordid><startdate>201701</startdate><enddate>201701</enddate><creator>Caplan, Arnold I.</creator><creator>Mason, Chris</creator><creator>Reeve, Brock</creator><general>Oxford University Press</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201701</creationdate><title>The 3Rs of Cell Therapy</title><author>Caplan, Arnold I. ; Mason, Chris ; Reeve, Brock</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5303-2ee0db1f383e344f3ad4f0a741e8ce8d4b3cabee66f5a47e2af436b285b9cc4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Baby boomers</topic><topic>Biotechnology industry</topic><topic>Bone marrow</topic><topic>Business models</topic><topic>Disease</topic><topic>FDA approval</topic><topic>GDP</topic><topic>Gross Domestic Product</topic><topic>Health care</topic><topic>Market positioning</topic><topic>Medical device industry</topic><topic>Medical equipment</topic><topic>Medical technology</topic><topic>Patients</topic><topic>Product lines</topic><topic>Regulation</topic><topic>Regulatory approval</topic><topic>Stem cells</topic><topic>Success</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caplan, Arnold I.</creatorcontrib><creatorcontrib>Mason, Chris</creatorcontrib><creatorcontrib>Reeve, Brock</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Stem cells translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caplan, Arnold I.</au><au>Mason, Chris</au><au>Reeve, Brock</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The 3Rs of Cell Therapy</atitle><jtitle>Stem cells translational medicine</jtitle><addtitle>Stem Cells Transl Med</addtitle><date>2017-01</date><risdate>2017</risdate><volume>6</volume><issue>1</issue><spage>17</spage><epage>21</epage><pages>17-21</pages><issn>2157-6564</issn><eissn>2157-6580</eissn><abstract>The 3Rs for a good education are “reading, 'riting, and 'rithmetic.” The basis for good health care solutions for the emergent field of cell therapy in the future will also involve 3Rs: regulation, reimbursement, and realization of value. The business models in this new field of cell therapy will involve these 3Rs. This article brings forth realities facing this new industry for its approaches to provide curative health care solutions. Stem Cells Translational Medicine 2017;6:17–21</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>28170173</pmid><doi>10.5966/sctm.2016-0180</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2157-6564 |
| ispartof | Stem cells translational medicine, 2017-01, Vol.6 (1), p.17-21 |
| issn | 2157-6564 2157-6580 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5442742 |
| source | Wiley Online Library - AutoHoldings Journals; DOAJ Directory of Open Access Journals; Access via Oxford University Press (Open Access Collection); EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central |
| subjects | Baby boomers Biotechnology industry Bone marrow Business models Disease FDA approval GDP Gross Domestic Product Health care Market positioning Medical device industry Medical equipment Medical technology Patients Product lines Regulation Regulatory approval Stem cells Success |
| title | The 3Rs of Cell Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T02%3A32%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%203Rs%20of%20Cell%20Therapy&rft.jtitle=Stem%20cells%20translational%20medicine&rft.au=Caplan,%20Arnold%20I.&rft.date=2017-01&rft.volume=6&rft.issue=1&rft.spage=17&rft.epage=21&rft.pages=17-21&rft.issn=2157-6564&rft.eissn=2157-6580&rft_id=info:doi/10.5966/sctm.2016-0180&rft_dat=%3Cproquest_pubme%3E2289828384%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2289828384&rft_id=info:pmid/28170173&rfr_iscdi=true |